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Mutations in the ER±Golgi Intermediate
Compartment Protein ERGIC-53 Cause Combined
Deficiency of Coagulation Factors V and VIII
both factors V and VIII is a distinct clinical entity first
described by Oeri et al. (1954). Affected patients demon-
strate a moderate bleeding tendency in association with
plasma levels of FV and FVIII (both antigen and activity)
in the range of 5%±30% of normal. Since this original
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report, more than 89 patients belonging to at least 58and David Ginsburg1,2,4,8
families have been described. Of the 58 families, 24 are1Department of Internal Medicine
of Mediterranean origin including 9 Italian and 9 Israeli2Department of Human Genetics
families. The remaining 34 families are from North3Department of Biological Chemistry
America, Europe, and Japan (Seligsohn, 1989). This dis-4Howard Hughes Medical Institute
order appears to be particularly prevalent among JewsUniversity of Michigan
of Middle Eastern and Sephardic origin living in IsraelAnn Arbor, Michigan 48109-0650
with an estimated frequency of 1:100,000 (Seligsohn5Institute of Thrombosis and Hemostasis
et al., 1982). Inheritance is autosomal recessive and isThe Chaim Sheba Medical Center, Tel-Hashomer
distinct from coinheritance of both FV deficiency (para-and Sackler Faculty of Medicine, Tel-Aviv
hemophilia) and FVIII deficiency (hemophilia A) (GirolamiIsrael
et al., 1976; Mazzone et al., 1982; Ozsoylu, 1983; Selig-6Biozentrum
sohn, 1989). Affected individuals are assumed to beUniversity of Basel
homozygous at a locus, which, in some manner, uniquelyBasel, Switzerland
regulates the expression of these two specific proteins.7Department of Blood Coagulation and
FV is synthesized primarily in megakaryocytes andHemophilia Centre
hepatocytes and is found in the plasma and a granulesUniversity Hospital
of platelets as a 330 kDa single chain polypeptide (ChiuPoliclinico 70124, Bari
et al., 1985). FVIII is most likely synthesized in the hepa-Italy
tocyte and reticuloendothelial cells (Wion et al., 1985;
Bontempo et al., 1987) and is processed upon secretion
from the cell to a heterodimer consisting of a carboxy-Summary
terminal±derived light chain of 80 kDa in a metal ion±
dependent association with a 200 kDa amino-terminal±Combined deficiency of factors V and VIII is an au-
derived heavy chain fragment. FV and FVIII circulate intosomal recessive bleeding disorder resulting from
plasma as inactive precursors that are activated throughalterations in an unknown gene on chromosome 18q,
limited proteolysis and subsequently assemble withdistinct from the factor V and factor VIII genes. ERGIC-
their respective substrates (prothrombin and factor X)53, a component of the ER±Golgi intermediate com-
and enzymes (factor Xa and factor IXa) on a negativelypartment, was mapped to a YAC and BAC contig con-
charged phospholipid surface. FVIII stability in plasmataining the critical region for the combined factors
requires a tight noncovalent interaction with the plasmaV and VIII deficiency gene. DNA sequence analysis
protein von Willebrand factor (vWF) (for review, seeidentified two different mutations, accounting for all
(Kaufman, 1998). Plasma FV does not require a similar
affected individuals in nine families studied. Immuno-
carrier protein, and its concentration exceeds that of
fluorescence and Western analysis of immortalized
FVIII by approximately 40-fold.
lymphocytes from patients homozygous for either of FV and FVIII are homologous proteins that have a
the two mutations demonstrate complete lack of ex- conserved domain organization. The A domains of FVIII
pression of the mutated gene in these cells. These share 40% amino acid identity with each other and to
findings suggest that ERGIC-53 may function as a mo-
the A domains of FV and also to the copper binding
lecular chaperone for the transport from ER to Golgi protein ceruloplasmin (Ortel et al., 1984). Both FV and
of a specific subset of secreted proteins, including FVIII contain 1 mol copper ion/mol protein, and at least
coagulation factors V and VIII. for FVIII, this copper ion is in the reduced form (Mann
et al., 1984; Tagliavacca et al., 1997). The FVIII C domains
Introduction also exhibit 40% identity to each other, and to the C
domains of FV, and share homology with proteins that
Coagulation factor V (FV) and factor VIII (FVIII) are both bind negatively charged phospholipids (Stubbs et al.,
required for the efficient function of the blood-clotting 1990). The B domains demonstrate little homology at
system. Genetic deficiency of FVIII results in classic the amino acid sequence level butare encoded by single
hemophilia (hemophilia A), an X chromosome±linked exons of similar length and are both heavily glycosylated
bleeding disorder afflicting z1 in 5000 males. Inherited (Gitschier et al., 1984; Cripe et al., 1992). FV and FVIII
FV deficiency, or parahemophilia, is a rare autosomal undergo similar and extensive posttranslational modifi-
recessive condition exhibiting a similar hemorrhagic cations that include formation and conserved pairing of
phenotype (Ginsburg, 1997). Combined deficiency of disulfide bonds (Kaufman, 1998), addition and complex
modification of multiple asparagine-linked oligosaccha-
ride residues (Pittman et al., 1994b), addition of multiple8 To whom correspondence should be addressed.
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serine/threonine linked oligosaccharides within the B had localized the gene to a 2.5 cM region between the
domain, and sulfation of multiple tyrosine residues genetic markers D18S1144 and D18S1109 (Nichols et
(Michnick et al., 1994; Pittman et al., 1994c). al., 1997). YAC clones spanning the 3.2 cM genetic inter-
The molecular basis for combined factors V and VIII val from D18S849 to D18S64 were identified from the
deficiency has been a puzzle since its first description in Human Physical Mapping Project at theWhitehead Insti-
1954 (Oeri et al., 1954). Chance coinheritance of classic tute for Biomedical Research/MIT Center for Genome
hemophilia A (FVIII deficiency) and parahemophilia (FV Research. PCR was used to confirm that the YAC clones
deficiency) has been reported in four families (Girolami obtained were positive for the appropriate markers, as
et al., 1976; Mazzone et al., 1982; Ozsoylu, 1983). How- reported. PFGE and Southern analysis determined the
ever, this explanation cannot account for the majority size of the YACs and enabled determination of thephysi-
of combined deficiency patients, for whom the genetic cal distancebetween markers spanning the critical inter-
pattern reflects simple autosomal recessive inheritance val. A complete setof overlapping YACs was established
due to a defect in a single gene. FV and FVIII are both with an estimated size of 3.0 megabases (Mb) between
proteolytically inactivated by activated protein C (APC). D18S849 and D18S64 (Figure 1), consistent with the
Thus, deficiency of protein C inhibitor, leading to unop- genetic distance of 3.2 cM determined previously using
posed increased activity of APC, seemed a logicalexpla- Multimap. A partial BAC contig was also constructed
nation for this disorder when first reported (Marlar and by screening a human BAC library with the seven genetic
Griffin, 1980). However, subsequent studies documented markers, four STSs, and 11 ESTs (see Figure 1) that were
normal protein C inhibitor levels in these patients and used to construct the YAC contig. Thirty-three clones
demonstrated that the initial observation of decreased were identified spanning the interval from D18S1144 to
levels was due to a laboratory artifact (Canfield and D18S64. A complete overlapping set of BAC clones was
Kisiel, 1982; Suzuki et al., 1983; Gardiner and Griffin, established for the interval D18S1103±D18S64. End
1984; Rahim Adam et al., 1985). The normal survival of clone sequences were determined for ten of the clones
exogenous coagulation factors when administered to by direct sequence analysis of whole BAC DNA. STSs
combined deficiency patients argues against an accel- were developed from the end clone sequences and used
erated clearance mechanism and suggests that this dis- to determine overlap between the clones. NotI digestion
order might be due to a common defect in biosynthesis followed by PFGE was used to determine the insert size
or secretion (Seligsohn, 1989). However, this latter ex- for a number of the BAC clones in the contig (Figure 1).
planation isdifficult to reconcile with themarkedly differ-
ent plasma levels and patterns of expression for these
two proteins. Identification of Candidate Genes for Combined
We recently localized the gene for combined factors Factors V and VIII Deficiency
V and VIII deficiency to the long arm of chromosome To begin the characterization of potential candidate
18 in nine unrelated Jewish families of Sephardic and genes lying within the YAC contig, 36 ESTs that mapped
Middle Eastern origin using a homozygosity mapping in radiation hybrid bins which would contain the entire
approach (Nichols et al., 1997). This localization was candidate interval of D18S1144±D18S1109 were identi-
subsequently confirmed in an independent study of 19 fied from the human transcript map (Schuler et al., 1996).
families from Iran, Pakistan, and Algeria (Neerman- Because the liver appears to be a primary site of synthe-
Arbez et al., 1997). We now report identification of sis for both FV and FVIII (Chiu et al., 1985; Wion et al.,
the gene responsible for combined factors V and VIII 1985), we hypothesized that the combined factors V and
deficiency and the characterization of two distinct VIII deficiency gene should also be expressed in that
founder mutations. The combined factors V and VIII defi-
tissue. Therefore, we focused our initial analysis on
ciency gene corresponds to a well-described marker of
those ESTs that had been isolated, at least in part, from
the endoplasmic reticulum±Golgi intermediate compart-
liver mRNA.Of the36 ESTs/genes, 19 fulfilled this criteria
ment, ERGIC-53 (Schweizer et al., 1988, 1990). ERGIC-
and were considered to be potential candidate genes53, a type 1 transmembrane protein with homology to
(Figure 1). The YAC and BAC clones comprising theleguminous lectins (Fiedler and Simons, 1994), exhib-
critical region contig were analyzed by PCR for each ofits mannose-selective and calcium-dependent binding
the 19 ESTs/genes. Of the 19 expressed sequences, 11(Arar et al., 1995; Itin et al., 1996) and has recently been
were shown to map to the candidate interval (Figure 1).hypothesized to play a role in the transport of glycopro-
Linkage analysis of 19 additional families by Neerman-teins through the secretory pathway.
Arbez et al. (1997) confirmed our localization of the com-
bined factors V and VIII deficiency gene to chromo-
some 18q and placed the gene between D18S849 and
D18S1103. In contrast, our analysis of an additional af-Results
fected individual from an Italian family identified a re-
combination between D18S1103 and D18S1155 (dataConstruction of Physical Map for Genomic Region
not shown) placing the gene between D18S1103 andContaining the Combined Factors V
D18S1109 (Figure 1) and excluding the segment fromand VIII Deficiency Gene
D18S849 to D18S1103 suggested by Neermaj-Arbez etIn order to identify the gene responsible for combined
al. (1997). The further narrowing of the candidate intervalfactors V and VIII deficiency, it was first necessary to
based on our additional patient resulted in the elimina-construct a physical map of the region (Figure 1). Previ-
ous genetic linkage studies and recombination analysis tion of 8 of the 11 ESTs as candidate genes.
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Figure 1. Physical Mapping of Critical Interval
At the top is shown the genetic linkage map for the 13 polymorphic markers used in the original linkage analysis (Nichols et al., 1997). The
X's indicate the critical recombinants placing the combined factors V and VIII deficiency gene in the 2.5 cM region between markers D18S1144
and D18S1109. The region between markers D18S849 and D18S64 is enlarged below. The location of individual polymorphic markers and
STSs (in black) and ESTs (in gray) are indicated. Complete YAC and partial BAC contigs were assembled as described in the text, with the
approximate scale indicated. YAC clones were sized by pulsed-field gel electrophoresis. YAC sizes were not determined for clones 777-F-12
and 754-A-6, which are reportedly chimeric with chromosome 14 and X, respectively. All BAC clones spanning the interval from D18S1103
to D18S64 (except 31J22, 400L15, and 328O20) were sized by pulsed-field gel electrophoresis. Dashed lines extending downward from the
polymorphic markers; STSs and ESTs at the top of the physical map indicate YAC clones and BAC clones that were positive for each marker.
Closed circles at the end of some BAC clones indicate end clone sequences.
Mutation Analysis for ERGIC-53 RNA PCR of fragment 2 (Table 1) yielded an aberrant
One of the ESTs that mapped to the recombinant interval PCR product in the Sephardic Jewish patient 6±3. This
(SHGC-12001, accession number X71661) corresponded product is approximately 150 base pairs larger than that
to the cDNA for ERGIC-53, a previously described resi- observed from the RNAs of two control individuals as
dent protein of the endoplasmic reticulum±Golgi inter- well as the two Middle Eastern Jewish patients (2-1 and
mediate compartment of unknown function (Schweizer 3-1) (Figure 3). DNA sequence analysis of this fragment
et al., 1988, 1990; Schindler et al., 1993; Itin et al., 1996). identified homozygosity for a 132 base pair insertion in
The complete coding sequence for ERGIC-53 was am- the Sephardic Jewish patient with GC at the 59 end and
plified by PCR in three overlapping fragments (Table 1) AG at the 39 end of the insertion as compared to the
using total RNA isolated from EBV-transformed B-lym- normals and Middle Eastern Jewish patients (Figure 3).
phocyte cultures established from two of the Middle Amplification of the corresponding region from genomic
Eastern Jewish patients (2-1 and 3-1 in Figure 1 of Nich-
DNA generated a 346 base pair fragment (214 base pairs
ols et al., 1997) and one of the Sephardic Jewish patients
of coding 1 132 base pairs of intron, see Table 1) in all
(6-3) with combined factors V and VIII deficiency and
samples. The intron sequence corresponds to the 132one normal individual. DNA sequence analysis was per-
bp insertion amplified from the mRNA of patient 6-3.formed on both strands for the entire coding region.
DNA sequence analysis of genomic DNA PCR productHomozygosity for a single base insertion of guanine in
confirmed homozygosity for the thymine-to-cytosinea stretch of four guanines from bases 86±89 (A of ATG
change at the consensus splice donor in the Sephardicinitiatior 5 11) was identified in both Middle Eastern
Jewish patient (Figure 3). No evidence of the correctlyJewish patients (See Figure 2). The single base insertion
spliced mRNA product is detected in patient 6-3 (Figurepredicts a frameshift at codon 30 resulting in a truncated
3), indicating that this mutation results in complete lossprotein containing only the first 30 N-terminal amino
of splicing of this intron. This mutation would predict aacids of ERGIC-53 followed by 71 residues in the new
reading frame leading up to the first stop codon. protein product that included the N-terminal 383 (of 510)
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Table 1. ERGIC-53 PCR Product Primers and Allele-Specific Oligonucleotides
Product Length Annealing Temp
Nucleotidesa Primer Sequences (bp) (8C)
PCR product
RNA PCR fragment 1 219±810 TCGCGTTCCAGAATCCAAG (F)b 829 56
AGGTTCAGTCAACTGGAAAG (R)
RNA PCR fragment 2 711±1593 TATCCCTGCACAAGGGCATT (F) 883 54
AATTCCCTCAAAACGACATC (R)
RNA PCR fragment 3 1484±2079 ATATCATGTATAGGTCTCAG (F) 596 52
TTGAAGTCTATTACCAGATC (R)
RNA PCR to detect splice mutation 990±1299 GCTAAGACAAGTCTTTGCAG (F) 320 54
TGAAGTGCTGTGTTGTCTCA (R)
DNA PCR to detect splice mutation 990±1203 GCTAAGACAAGTCTTTGCAG (F) 214 1 132 (intron) 55
TCTCAGAATCTCATGCTGAG (R)
DNA PCR to detect G insertion 50±139 TCTGCGCCTTGCTGCTGTCA (F) 90 62
mutation
CGAAACGGCGATGTGGCAAC (R)
Allele-Specific oligonucleotides (ASO)
ASO to detect G insertion mutation 80±93 (1G) TCGTCCGGGGGCGAC
ASO to detect normal sequence 80±94 TCGTCCGGGGCGACG
ASO to detect T-to-C splice donor 1144±1149 1 GGGCAGGCGGGCTTG
mutation 1±9 (intron)
ASO to detect normal splice donor 1144±1149 1 GGGCAGGTGGGCTTG
1±9 (intron)
a Based on ERGIC-53 cDNA (GDB accession number X71661) sequence with A of initiatior ATG 5 11 (nucleotide 21 of X71661).
b (F) and (R) indicate forward (sense) and reverse (antisense) primers.
amino acids of ERGIC-53 followed by 18 residues en- DNA samples from members of all nine families were
screened by hybridization with allele-specific oligonu-coded by the unspliced intron leading up to the first in-
frame stop codon. cleotide probes specific for the two mutations identified
above (Table 1). All 9 affected individuals from the 4Our previous genetic linkage analysis of nine Sephar-
dic Jewish and Middle Eastern Jewish families identified Middle Eastern Jewish families were homozygous for
the ERGIC-53 codon 30 G insertion mutation while all 6two distinct haplotypes segregating with the disease,
suggesting the possibility of two independent founder affected individuals from the 5 Sephardic Jewish fami-
lies were homozygous for the splice donor mutationchromosomes. The five Sephardic Jewish families shared
a haplotype extending for at least 6.5 cM including the (Figure 4). In all cases, parents of the affected individuals
were heterozygous carriers of the corresponding muta-markers D18S1103±D18S862 (Figure 1) while the four
Middle Eastern Jewish families shared a different haplo- tions. All individuals homozygous for either mutation
were clinically affected with combined factors V and VIIItype covering a 0.4±2.2 cM region containing only the
markers D18S1103 and D18S1155. These data sug- deficiency, confirming 100% penetrance for this disor-
der. Analysis of an additional Middle Eastern Jewishgested that the origin of the mutation in the Middle
Eastern Jewish families may be more ancient than that family originally from Iran, not included in our original
mapping report (Nichols et al., 1997), again identifiedin the Sephardic Jewish families (Nichols et al., 1997).
Figure 2. Frameshift Mutation in ERGIC-53
(A) Sequence analysis of RT-PCR products of
fragment 1 of the ERGIC-53 coding sequence
(Table 1) derived from a Sephardic Jewish
combined factors V and VIII deficiency pa-
tient (6-3), two Middle Eastern Jewish pa-
tients (2-1 and 3-1), and a control individual.
Numbers from individual patients correspond
to those used in the pedigrees shown in Fig-
ure 1 of Nichols et al. (1997). The Middle East-
ern Jewish patients are both homozygous for
a G insertion in a run of 4 G's corresponding
to base pairs 86±89 of the ERGIC-53 cDNA.
(B) The single base insertion predicts a
frameshift at codon 30 resulting in a truncated
protein containing only the first 30 N-terminal
amino acids of ERGIC-53 followed by 71 resi-
dues in the new reading frame leading up to
the first stop codon.
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Figure 3. Splice Donor Mutation in ERGIC-53
(A) Ethidium bromide±stained agarose gel of
RT-PCR product for ERGIC-53 ªRNA PCR
fragment 2º (Table 1) amplified from RNA de-
rived from combined factors V and VIII defi-
ciency patients 6-3, 2-1, and 3-1 (see legend
to Figure 2). The marker (M) is HaeIII digest
of FX174.
(B) DNA sequence analysis of PCR products
for the corresponding region of genomic DNA
(ªDNA PCR to detect splice mutation,º Table
1). Patient 6-3 is homozygous for a thymine-
to-cytosine substitution in the highly con-
served splice donor consensus. Analysis of
the RT-PCR product in (A) is consistent with
complete failure to remove this intron in pa-
tient 6-3.
(C) The predicted translation product from the
mutant allele contains the N-terminal 383 (of
510) amino acids of ERGIC-53 followed by
18 residues encoded by the unspliced intron
leading up to the first in-frame stop codon.
homozygosity for the Ginsertion mutation in theaffected was seen in the normalcells with the ERGIC-53antibody,
no evidence of ERGIC-53 protein expression was de-individual with both parents shown to be heterozygous
carriers (data not shown). tected in either patient cell line. Western analysis of cell
extracts prepared from the EBV-immortalized B-lym-
phocytes using an anti-ERGIC-53 rabbit polyclonal anti-Analysis of ERGIC-53 Expression in Lymphocyte Cell
Lines Derived from Patients with Combined serum also confirmed complete absence of ERGIC-53
immunoreactive protein (Figure 6). These results indi-Factors V and VIII Deficiency
To determine whether the two mutations identified in the cate that both the G insertion mutation and the splice
donor mutation result in complete loss of immunologi-ERGIC-53 gene resulted in lossof ERGIC-53expression,
immunofluorescence of EBV-immortalized B-lymphocytes cally recognizable ERGIC-53 expression. SDS polyacryl-
amide gel electrophoresis and Coomassie staining de-derived from patients 2-1 (Middle Eastern Jewish, G
insertion mutation), 6-3 (Sephardic Jewish, splice donor tected no obvious differences in protein content between
conditioned media of ERGIC-53 deficient and controlmutation), and a control individual was performed. Cells
were stained with a monoclonal antibody to ERGIC-53 EBV-immortalized cell lines (data not shown).
(Schweizer et al., 1988), a monoclonal antibody to a
control ER protein, p63 (Schweizer et al., 1993), and a Discussion
negative control antibody (Figure 5). All three cell lines
showed positive cytoplasmic staining with the p63 anti- The demonstration of homozygosity for an inactivating
mutation in all of the affected patients from nine familiesbody. Though a similar cytoplasmic pattern of staining
Figure 4. Allele-Specific Oligonucleotide Hy-
bridization Analysis of Combined Factors V
and VIII Deficiency Families
ERGIC-53 PCR products derived from mem-
bers of all nine Sephardic and Middle Eastern
Jewish families originally reported in Nichols
et al. (1997) were spotted onto nylon mem-
branes and hybridized with oligonucleotides
specific for either the G insertion mutation
(A), the splice donor mutation (C), or the cor-
responding normal alleles (B and D, respec-
tively). Grid lines on the filters demark the
families, labeled 1±9 (dashed lines, Middle
Eastern Jewish; solid lines, Sephardic Jew-
ish). Affectedpatients are indicated by circled
dots with other dots corresponding to unaf-
fected siblings or obligate carrier parents. All
affected individuals from the Middle Eastern
Jewish families (2, 3, 4, and 7) are homozy-
gous for the G insertion mutation, with all un-
affected family members either heterozygous
or homozygous for the normal allele. Though
negative for the G insertion, all the affected
individuals from the Sephardic Jewish fami-
lies (1, 5, 6, 8, and 9) are homozygous for the
splice donor mutation.
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Figure 5. Immunofluorescence Analysis for ERGIC-53 in EBV-Immortalized Lymphocytes Established from Patients with Combined Factors
V and VIII Deficiency
EBV-immortalized lymphocytes established from individuals 6-3, 2-1 (See Figure 2), and a control individual were stained with a monoclonal
antibody to ERGIC-53 (G1/93), a monoclonal antibody to p63 (G1/296), or a negative control antibody (monoclonal anti T7-Tag). All three cell
lines demonstrate a similar pattern of positive staining with G1/296. In contrast, no G1/93 staining is seen in cells derived from the two
combined factors V and VIII deficiency patients.
clearly establishes ERGIC-53 as the gene responsible al., 1988). This antibody specifically labels pleomorphic
membrane structures between the ER and Golgi, whichfor combined factors V and VIII deficiency. This surpris-
are collectively referred to as the intermediate compart-ing finding identifies the molecular mechanism for this
ment or vesicular-tubular cluster (VTC) (Schweizer et al.,disorder as a defect in a common pathway for the intra-
1990; Bannykh and Balch, 1997). A number of studiescellular trafficking of these two blood coagulation fac-
suggest that these structures mark a distinct compart-tors. In addition, these data demonstrate a role for a
ment in the transport between ER and Golgi and thatprotein within the ER±Golgi intermediate compartment
this is the site of a sequential transition from COPII toin the transport of a specific subset of secreted glyco-
COPI coated vesicles (Scales et al., 1997).proteins.
ERGIC-53 is a type 1 transmembrane protein that ex-
ists as homodimers and homohexamers (Schweizer etThe Function of ERGIC-53 and the ER±Golgi
al., 1988), has homology to leguminous lectins (FiedlerIntermediate Compartment
and Simons, 1994), and exhibits mannose-selective andERGIC-53 was first identified as a 53 kDa protein recog-
calcium-dependent binding (Arar et al., 1995; Itin et al.,nized by the monoclonal antibody, G1/93 (Schweizer et
1996). Its amino acid sequence also contains determi-
nants for anterograde transport and a dilysine ER re-
trieval signal, leading to constitutive recycling between
the ER, intermediate compartment, and Golgi (Lippin-
cott-Schwartz et al., 1990; Schindler et al., 1993; Itin et
al., 1995). ERGIC-53 is identical to a mannose-specific
membrane lectin isolated from human monocytes, MR60
Figure 6. Western Analysis of EBV-Immortalized Lymphocytes (Arar et al., 1995); and close homologs have been identi-
Cell extracts of EBV-immortalized lymphocytes from two control fied in rat (p58) (Saraste et al., 1987; Lahtinen et al.,
individuals (N), and three combined factors V and VIII deficiency 1996), Xenopus laevis (Lahtinen et al., 1996), and Caeno-
patients (6-3, 2-1, and 3-1; see legend to Figure 2) were fractionated rhabditis elegans (GenBank accession number Z81097).
on a reducing SDS-polyacrylamide gel, tranferred to nitrocellulose,
Recent mutagenesis studies suggest that ERGIC-53 in-and probed sequentially for ERGIC-53 followed by p63. All five cell
teracts directly with the COPII coat component Sec23p,lines demonstrate a similar pattern of positive staining for p63. In
which may direct it to vesicles budding from the ERcontrast, no ERGIC-53 staining is seen in cells derived from the
three combined factors V and VIII deficiency patients. (Kappeler et al., 1997). An antibody to the ERGIC-53
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cytoplasmic tail was recently shown to block the trans- pathway? In addition to the abnormalities identified in
patients with combined factors V and VIII deficiency, itport of vesicular stomatitis virus glycoprotein from the
seems likely that a defect in at least a limited subset ofER to Golgi and to block recruitment of COPI to the
other proteins may also be present. Perhaps the corre-intermediate compartment in permeabilized cells (Tis-
sponding reductions in level for these latter proteins aredale et al., 1997). These studies suggested that ERGIC-
more subtle. Alternatively, levels in the range of 5%±53 may be required for the coupled exchange of COPII
30%, whichin the caseof FV and FVIII result in significantfor COPI coats during segregation of anterograde and
bleeding, may fail to produce a recognizable phenotyperetrograde transported proteins and thus may play an
for other proteins regulated through this pathway.essential role in the general transport of glycoproteins
It is important to note that the two mutations identifiedthrough the secretory pathway. In contrast, our data
in this report both appear to result in complete lossindicate that ERGIC-53 is only required for the efficient
of ERGIC-53. Taken together with the observation ofsecretion of a specific subset of glycoproteins, rather
residual FV and FVIII activity in the corresponding pa-than a more general role in ER-to-Golgi transport. The
tients (Seligsohn et al., 1982), these results suggest thatnormal levels of other plasma proteins in combined
ERGIC-53 enhances the efficiency of a sorting eventfactors V and VIII±deficient patients demonstrate that
during the transport of these proteins but is not abso-ERGIC-53 is not essential for the integrity of the ER or
lutely required for secretion of FV and FVIII.for the intracellular transport of most secreted proteins.
Is there a unique shared property between coagula-Anterograde transport from the ER has been assumed
tion factors V and VIII that target them both to this com-to be the default pathway for the bulk flow of secreted
mon secretory pathway? These proteins share up toproteins, with sorting occurring primarily in the Golgi via
40% overall sequence identity across the A and C do-specific signals that direct retrieval to earlier compart-
mains. The plasma protein ceruloplasmin, which alsoments or forward transport to the lysosome or plasma
contains similar A domains, exhibits normal levels inmembrane (Pfeffer and Rothman, 1987; Schekman and
these patients (Seligsohn, 1989). As noted above, theMellman, 1997). However, studies of albumin (Mizuno
tissue-specific patterns and levels of expression ofand Singer, 1993) and vesicular stomatitis virus glyco-
these two proteins differ significantly. In addition, majorprotein (Balch et al., 1994) secretion and, more recently,
differences in the intracellular processing and biosyn-
in S. cerevisiae (Kuehn and Schekman, 1997) suggest
thesis of these two proteins and their interactions with
selective packaging of cargo upon export from the ER.
resident ER proteins have been documented (for review,
Yeast mutants lacking Emp24p, a component of COP
see Kaufman, 1998).
II±coated vesicles, are viable but exhibit reduced deliv-
Of note, factors V and VIII both contain a central B
ery of several specific proteins to the Golgi, with the
domain encoded by a single z 3 kb exon. Though only
transport of other proteins apparently unaffected. These weakly homologous at the amino acid level, the length
results suggest the presence of a cellular machinery for of these segments is conserved. In addition, both B
the specific sorting of protein cargo into ER-derived domains are extensively glycosylated with 18 and 25
vesicles (Schimmoller et al., 1995). Mutations in the potential N-linked sites in FVIII and FV, respectively, and
V-snare Sec22p or alterations in the level of either the multiple O-linked structures. Recombinant B domain±
GTPase Sar1p or its guanine nucleotide exchange factor deleted FV and FVIII retain coagulation activity, and the
Sec12p that mediate vesicle budding affect the packag- function of the B domain remains unknown (Toole et
ing of selective cargo to varying degrees (Campbell and al., 1986; Pittman et al., 1994a). Perhaps this shared
Schekman, 1997). In another recent study, analysis of segment is responsible for the interaction of these two
a panel of mutant alleles in SEC21, a component of proteins with ERGIC-53, possibly through a lectin-like
S. cerevisiae COPI, identified several variants that ex- function, consistent with the apparent affinity of ERGIC-
hibit striking, cargo-selective ER-to-Golgi transport de- 53 for mannose residues (Itin et al., 1996), though inhibi-
fects. The authors suggest that COPI may play an indi- tion of mannose trimming by inhibitors does not affect
rect role in anterograde transport, perhaps by mediating the secretion of FV or FVIII (Pittman et al., 1994b).
retrieval of other factors that are required for the packag-
ing of selected proteins into COPII vesicles leaving the Human Genetics of Combined Factors V
ER (Gaynor and Emr, 1997). and FVIII Deficiency
The results of our study suggest that ERGIC-53 may Our previous genetic analysis mapped the combined
be serving a similar function for a specific subset of factors V and VIII deficiency gene to the long arm of
proteins in mammalian cells, including coagulation fac- chromosome 18 and identified two distinct haplotypes,
tors V and VIII. ERGIC-53 could interact directly with suggesting either two distinct founder chromosomes,
these target proteins, directing them to COPII vesicles or a single ancient founder with a recent split to form
budding from the ER. Alternatively, ERGIC-53 could fa- the two populations analyzed in our study (Nichols et
cilitate retrieval of other factors from post-ER compart- al., 1997). The identification of distinct mutations corre-
sponding to each haplotypeconfirm the former hypothe-ments, which in turn direct FV and FVIII for selective
sis, documenting a common founder for the combinedpackaging in the ER.
factors V and VIII deficiency mutation among Sephardic
Jews and a different founder for the disease among
Potential Interactions of ERGIC-53 non-Sephardic Middle Eastern Jews. Future studies of
with FV and FVIII additional combined factors V and VIII deficiency pa-
Are factors V and VIII the only proteins that require tients in the Mediterranean basin (Seligsohn, 1989; Neer-
man-Arbez et al., 1997) may provide interesting insightsERGIC-53 for efficient transport through the secretory
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After incubating at room temperature for $5 min, 1/5 vol of chloro-into the evolutionary history of this disease. Perhaps the
form was added followed by vigorous shaking and incubation forapparent increased prevalence of this disorder in this
2±3 min. The aqueous phase was removed after centrifugation andregion will be explained by common founder effects, or
precipitated withÃ volume 100% isopropanol. The RNA was pelleted
a selective advantage for heterozygotes. by centrifugation and washed once with 75% isopropanol. After air-
The unexpected identification of ERGIC-53 as the drying, the RNA was dissolved in DEPC-treated deionized water.
Concentration was determined by spectrophotometry. Reversegene responsible for combined factors V and VIII defi-
transcriptase (RT) reaction was performed using 1 mg total RNA asciency provides evidence for the selective packaging of
template in a 40 ml reaction containing 2 mg oligo dT, 625 mM eachproteins for transport through the secretory pathway
dNTP, 13 RT buffer (50 mM Tris-Cl [pH 8.5], 8 mM MgCl2, 30 mMand suggests a central role for the intermediate com-
KCl, 1 mM DTT), and 25 U AMV reverse transcriptase (Boehringer
partment in this process. Future advances stemming Mannheim). After incubation at 418C for 1 hr, PCR was performed
from these findings should enhance the understanding using 10 ml of the RT reaction in a 50 ml reaction containing 100 ng
of the appropriate forward and reverse primer (See Table 1), 13of factors V and VIII biosynthesis, which may lead to
adjustment buffer (44 mM KCl, 0.01% gelatin, 0.1% Triton X-100),improved strategies for the production of recombinant
100 mM each dNTP, and Taq polymerase. Cycling was performedfactor VIII as well as gene therapy approaches for the
using an MJ Research PTC-100 96V thermocycler (Watertown, MA)treatment of hemophilia and related bleeding disorders.
with 1 min each of denaturation, annealing, and elongation for 35
cycles. PCR products were electrophoresed through 2% agarose
and visualized by staining with ethidium bromide. Sequence of PCR
Experimental Procedures products was determined either manually using the Thermo Seque-
nase radiolabeled terminator cycle sequencing kit (Amersham Life
Physical Mapping Science, Arlington Heights, IL) or using automated sequence analy-
Yeast Artificial Chromosomes (YACs) sis by the University of Michigan DNA Sequencing Core after purifi-
A complete YAC contig spanning the genetic interval D18S849± cation using the QIAquick PCR Purification Kit (QIAGEN, Santa Clar-
D18S64 was constructed by PCR and pulsed-field gel electrophore- ita, CA)
sis (PFGE) analysis. In brief, six YACs clones known to span the
interval (Whitehead Institute for Biomedical Research/MIT Center
DNA PCR and Allele-Specific Oligonucleotidefor Genome Research) were obtained from Research Genetics
(ASO) Hybridization(Huntsville, AL), streaked to single colonies, and cultured as pre-
Twenty nanograms of total genomic DNA, prepared as previouslyviously described (Chandrasekharappa et al., 1992). Seven of the
described (Nichols et al., 1997), was amplified by PCR in a 20 mlshort tandem repeat markers (STRs) used in the previous genetic
reaction as previously described (Nichols et al., 1996) using thelinkage analysis (Nichols et al., 1997), as well as four sequence-
appropriate forward and reverse primers (See Table 1). Cycling con-tagged sites (STSs) and 11 expressed sequence tags (ESTs), were
ditions were 1 min each of denaturation, annealing, and elongationplaced on the YAC contig by PCR of total genomic yeast DNA,
for 35 cycles with a final extension of 5 min. After PCR, ASO hybrid-prepared as previously described (Chandrasekharappa et al., 1992),
ization analysis was performed essentially as described (Cooney etcontaining the YAC cloneof interest. After agarose plug preparation,
al., 1991) using oligonucleotides corresponding to both normal andindividual YAC clones were sized by PFGE and Southern analysis
mutant sequences (Table 1).using as probe a 2.7 kb PvuII±Bam HI fragment of pBR322, which
also corresponds to the left arm of the pYAC4 vector.
ImmunofluorescenceBacterial Artificial Chromosomes (BACs)
Immunofluorescence of EBV-immortalized B lymphocyte culturesA human BAC library (Research Genetics, Huntsville, AL) was
established using standard methods (Sugden and Mark, 1977) fromscreened by PCR to construct a partial BACcontig across the candi-
patients 2-1 and 6-3 (Nichols et al., 1997) and two control individualsdate interval. Thirty-two BAC clones were identified by screening
was performed as follows. Immortalized cells were resuspended inwith the STRs, STSs, and ESTs used to construct the YAC contig.
5% BSA in phosphate-buffered saline (PBS), and 1 3 105 wereClones of interest were obtained from Research Genetics and cul-
applied to slides using a Cytospin3 (Shandon, Pittsburgh, PA). Aftertured as previously described (Kim et al., 1992, 1996; Shizuya et al.,
air drying for 30 min on ice, the cells were fixed in 4% paraformalde-1992). Sizes of BAC clones were determined by PFGE of NotI di-
hyde in PBS for 20 min on ice. The slides were rinsed once in PBSgested BAC DNA, which separates the 7.3 kb pBeloBAC11 vector
for 5 min, once in 50 mM NH4Cl in PBS for 20 min, and once infrom the insert fragment(s). Sequence of BAC clone ends was deter-
double distilled deionized water, all at room temperature. The cellsmined using automated sequence analysis of whole BAC clones by
were permeabilized with absolute methanol on ice for 20 min, rehy-the University of Michigan DNA Sequencing Core after purification
drated with three 5 min rinses in PBS at room temperature, andof BAC DNA using the Plasmid Maxi Kit (QIAGEN, Santa Clarita,
blocked for 20 min at room temperature in 2% normal goat serum,CA) with subsequent phenol/chloroform extractions and ammonium
0.05% Triton X-100, and 0.05% Tween 20 in PBS. After blocking,acetate/ethanol precipitation. STSs developed from the BAC end
the cells were incubated with a 1/50 dilution of monoclonal anti-clone sequences were used to assist in contig construction. While a
ERGIC-53 antibody G1/93 (Schweizer et al., 1988), a 1/50 dilutioncomplete, overlapping set of clones was established for the interval
of monoclonal anti-p63 antibody G1/296 (Schweizer et al., 1993), orD18S1103±D18S64, only a partialcontig was completed for the inter-
a 1/200 dilution of a negative control antibody (monoclonal anti-T7val D18S849±D18S1103.
tag, Novagen, Madison, WI) in blocking solution overnight at 48C.Expressed Sequence Tags (ESTs)
After overnight incubation, the slides were washed three times atNineteen ESTs cloned from liver libraries were identified from the
room temperature in PBS. The cells were incubated in a 1/200 dilu-human transcript map (accessed at The National Center for Biotech-
tion in blocking solution of fluorescein-conjugated goat IgG fractionnology Information Website) (Schuler et al., 1996) as potentially map-
to mouse IgG (ICN, Aurora, OH) for 1 hr at room temperature. Afterping to the candidate interval. PCR primers were synthesized by
three 5 min washes in PBS, the slides were air dried and mountedthe University of Michigan Oligonucleotide Synthesis Core. PCR
with Immunofluore (ICN, Aurora, OH). The cells were visualized usinganalysis using EST-specific primer pairs of the clones comprising
a Meridian Instruments Ultima confocal microscope (Meridian In-the YAC and BAC contigs was used to determine those ESTs con-
struments, Okemos, MI).tained within the candidate interval.
Western Blotting
Cell extracts were fractionated on 8% reducing SDS-polyacrylamidePCR of Reverse Transcribed Lymphocyte RNA
Total RNA was prepared from patient and normal EBV-immortalized gel as previously described (Dorner and Kaufman, 1990). Western
blot analysis was performed with a polyclonal anti-ERGIC-53 rabbitB lymphocytes using TRIZOL Reagent (GIBCO BRL). In brief, z40 3
106 cells were pelleted and resuspended in 4 ml TRIZOL Reagent. antiserum/HRP-conjugated goat anti-rabbit antiserum (Boehringer
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Mannheim Biochemicals, Indianapolis, IN) followed by a monoclonal Girolami, A., Violante, N., Cella, G., and Patrassi, G. (1976). Com-
bined deficiency of factor V and factor VIII. A report of another case.anti-p63/HRP-conjugated goat anti-mouse antiserum (Boehringer
Blut 32, 415±422.Mannheim Biochemicals, Indianapolis, IN). Visualization was per-
formed using the ECL Western blotting detection reagents (Amer- Gitschier, J., Wood, W.I., Goralka, T.M., Wion, K.L., Chen, E.Y., Ea-
sham Life Science, Arlington Heights, IL). ton, D.H., Vehar, G.A., Capon, D.J., and Lawn, R.M. (1984). Charac-
terization of the human factor VIII gene. Nature 312, 326±330.
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